Beranda › Kanker Kepala dan Leher › Massachusetts
Uji klinis Kanker Kepala dan Leher di Massachusetts
24 studi untuk Kanker Kepala dan Leher mencari peserta di lokasi di Massachusetts.
Kota di Massachusetts
Teks studi resmi (Bahasa Inggris)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site #0131, Boston
- Site#0101, Boston
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06788990The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07059884A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07090499First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06657222Toripalimab With Chemotherapy for Sinus Cancer
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT06940180PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT06239220A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626Jump: MR Simulation For Radiation Therapy Master Protocol
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT04545957PDT For Induction Therapy For Head And Neck Cancer
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT07214987First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT05768139Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Dana-Farber Cancer Institute, Boston
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jun 2026 · NCT07675967Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT06993844Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT05726370A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Massachusetts General Hospital,, Boston
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT03093116A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Worcester
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Mei 2026 · NCT06256588Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06239194Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- Dana Farber Cancer Institute, Boston
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT03875716Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy
- Brigham and Women's Hospital, Boston
Menerima peserta
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 12 Feb 2026 · NCT07405645Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Menerima pesertaFase awal 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Jan 2026 · NCT05553782SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2025 · NCT05941507Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Dana Farber/Partners Cancer Care Inc, Boston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Agu 2025 · NCT04429542Comprehensive Outcomes for After Cancer Health
- Dana Farber Cancer Institute, Boston
Menerima pesertaSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Des 2024 · NCT05349227Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.